Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I, Gnjatic S, Krammer F, Tuballes K, Carreño JM, Satyanarayan S, Filomena S, Staker E, Tcheou J, Miller A, Fabian M, Safi N, Nichols J, Patel J, Krieger S, Tankou S, Horng S, Klineova S, Beck E, Merad M, Lublin F. Katz Sand I, et al. Among authors: lublin f. Mult Scler Relat Disord. 2023 Feb;70:104486. doi: 10.1016/j.msard.2022.104486. Epub 2022 Dec 28. Mult Scler Relat Disord. 2023. PMID: 36628884 Free PMC article.
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Nicholas J, Lublin F, Klineova S, Berwaerts J, Chinnapongse R, Checketts D, Javaid S, Steinerman JR. Nicholas J, et al. Among authors: lublin f. Mult Scler Relat Disord. 2023 Jul;75:104745. doi: 10.1016/j.msard.2023.104745. Epub 2023 May 1. Mult Scler Relat Disord. 2023. PMID: 37209500 Free article. Clinical Trial.
MS becomes a treatable disease: 30 years later.
Lublin FD, Krieger SC. Lublin FD, et al. Mult Scler. 2023 Jun;29(7):789-792. doi: 10.1177/13524585231174781. Epub 2023 May 26. Mult Scler. 2023. PMID: 37232509
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Hua LH, Bar-Or A, Cohan SL, Lublin FD, Coyle PK, Cree BA, Meng X, Su W, Cox GM, Fox RJ. Hua LH, et al. Among authors: lublin fd. Mult Scler Relat Disord. 2023 Jul;75:104766. doi: 10.1016/j.msard.2023.104766. Epub 2023 May 16. Mult Scler Relat Disord. 2023. PMID: 37245350 Free article. Clinical Trial.
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Cutter G, Rudick RA, de Moor C, Singh CM, Fisher E, Koster T, Lublin FD, Wolinsky JS, McFarland H, Jacobson S, Naylor ML. Cutter G, et al. Among authors: lublin fd. Mult Scler J Exp Transl Clin. 2023 Apr 27;9(2):20552173231169463. doi: 10.1177/20552173231169463. eCollection 2023 Apr-Jun. Mult Scler J Exp Transl Clin. 2023. PMID: 37139460 Free PMC article.
Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?
Bsteh G, Krajnc N, Altmann P, Hendin B, Bharadia T, Jaruszowic S, Lublin F, Oh J, Parow D, Ribbens A, Shields A, Smeets D, Thouvenot E, Chan A, Berger T. Bsteh G, et al. Among authors: lublin f. Eur J Neurol. 2024 Dec;31(12):e16526. doi: 10.1111/ene.16526. Epub 2024 Oct 24. Eur J Neurol. 2024. PMID: 39445673 Free PMC article. Review.
301 results